Last reviewed · How we verify
NCT06190314: ViBEVC
SERUM VITAMIN B12 LEVELS IN PATIENTS WITH HEMORRHAGIC VS ISCHEMIC CEREBROVASCULAR EVENT.
trial testing Measure serum vitamin b12 levels in Cerebrovascular Event in 100 participants. Status unknown.
1 July 2024
Quick facts
| Lead sponsor | Hospital General de Mexicali |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 13 November 2023 |
| Primary completion | 1 July 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Measure serum vitamin b12 levels
Conditions studied
- Cerebrovascular Event — all drugs for Cerebrovascular Event →
- Vitamin b12 — all drugs for Vitamin b12 →
- Hemorrhagic Stroke — all drugs for Hemorrhagic Stroke →
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Hospital General de Mexicali
Who can join
18 and older, any sex, with Cerebrovascular Event or Vitamin b12. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cerebral vascular events (CVA) have a high prevalence in our environment; they are the first cause of disability and the second cause of death in the world (6.6 million deaths). 71% of all strokes worldwide correspond to the ischemic type, which is defined as an infarction in the brain, spinal cord or retina; The remaining 10-40% are hemorrhagic and are due to rupture of cerebral arteries. Until epidemiological week 35 of 2022, 34,643 cases were reported in Mexico, for this week in 2021, 26,462 cases had been reported. Baja California is among the first three places in the country with the highest number of reported cases, the majority corresponding to the male sex. The key clinical characteristic is the sudden appearance of a focal neurological deficit. Imaging studies such as head computed tomography or magnetic resonance imaging allow us to differentiate the subtype and mechanism of CVD since treatment differs markedly between CVD of ischemic origin and that of hemorrhagic origin. Vitamin B12 or cobalamin is a tetrapyrrole cofactor; One of its functions is to participate in the metabolism of homocysteine, which has been reported in various studies and it has been shown that high levels of this increase the risk of vascular diseases, such as stroke. On the other hand, vitamin B12 deficiency can lead to platelet dysfunction, causing significant bleeding. There are few protocols that have sought the direct association of cobalamin with CVD and even fewer with the hemorrhagic type. This condition is one of the main causes of admission to the Emergency Service of the General Hospital of Mexicali where they are given the necessary attention such as performing imaging studies and taking laboratory samples and based on the results the treatment to be followed is decided; However, measurements of vitamin B12 levels are not performed in this population. If the association is demonstrated, it could be implemented as a preventive measure for cerebral vascular events.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06190314
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebrovascular Event
Currently open trials in the same condition.
- NCT06308952 — Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation · Phase 4 · recruiting
- NCT06336174 — Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study · recruiting
Other Hospital General de Mexicali trials
Trials by the same sponsor.
- NCT07245095 — Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy · Phase 2 · recruiting
- NCT06622525 — Use of Sodium Bicarbonate as Prophylaxis for Kidney Damage in Patients With Heatstroke · NA · recruiting
- NCT05398055 — Efficacy of Azithromycin Plus Doxycycline Versus Doxycycline Plus Placebo in Patients With Rocky Mountain Spotted Fever · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06190314 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital General de Mexicali
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06190314.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing